NZ630828A - Compounds and methods for treating aberrant adrenocartical cell disorders - Google Patents
Compounds and methods for treating aberrant adrenocartical cell disordersInfo
- Publication number
- NZ630828A NZ630828A NZ630828A NZ63082813A NZ630828A NZ 630828 A NZ630828 A NZ 630828A NZ 630828 A NZ630828 A NZ 630828A NZ 63082813 A NZ63082813 A NZ 63082813A NZ 630828 A NZ630828 A NZ 630828A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- adrenocartical
- compounds
- cell disorders
- treating aberrant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614269P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/031068 WO2013142214A1 (en) | 2012-03-22 | 2013-03-13 | Compounds and methods for treating aberrant adrenocartical cell disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630828A true NZ630828A (en) | 2016-10-28 |
Family
ID=48014328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630828A NZ630828A (en) | 2012-03-22 | 2013-03-13 | Compounds and methods for treating aberrant adrenocartical cell disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9107883B2 (enExample) |
| EP (1) | EP2838523A1 (enExample) |
| JP (2) | JP6234987B2 (enExample) |
| CN (2) | CN106236741A (enExample) |
| AU (2) | AU2013235535B2 (enExample) |
| BR (1) | BR112014023517B1 (enExample) |
| CA (1) | CA2867668A1 (enExample) |
| HK (1) | HK1206607A1 (enExample) |
| IN (1) | IN2014DN08604A (enExample) |
| MX (1) | MX355129B (enExample) |
| NZ (1) | NZ630828A (enExample) |
| WO (1) | WO2013142214A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2748238B2 (ja) | 1994-12-20 | 1998-05-06 | 新興機械工業株式会社 | ばね製造装置の足起こし装置 |
| BR112014023517B1 (pt) * | 2012-03-22 | 2020-12-01 | The Regents Of The University Of Michigan | Usos de cloridrato de n-(2,6-bis(1-metiletil)fenil)-n-((1-(4-(dimetilamino)fenil)ciclopentil) metil)ureia para tratar distúrbios das células do córtex adrenal anormais |
| WO2015048543A1 (en) * | 2013-09-26 | 2015-04-02 | Atterocor, Inc. | Treating disorders associated with aberrant adrenocortical cell behavior |
| MX2017003916A (es) * | 2014-09-26 | 2017-06-30 | Millendo Therapeutics Inc | Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. |
| WO2016164476A2 (en) * | 2015-04-06 | 2016-10-13 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| WO2017011302A1 (en) * | 2015-07-10 | 2017-01-19 | Millendo Therapeutics, Inc. | Enhanced bioavailability of n-(2,6-bis(1-methylethyl) phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl) methyl)urea hydrochloride |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| US10231983B1 (en) | 2018-08-22 | 2019-03-19 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US11202787B2 (en) | 2018-07-02 | 2021-12-21 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US10780097B2 (en) | 2018-07-02 | 2020-09-22 | Corcept Therapeutics, Inc. | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| JP7784121B2 (ja) * | 2019-06-11 | 2025-12-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を治療するための組成物および方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5015644A (en) | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| BRPI0719941A2 (pt) * | 2006-12-06 | 2014-04-22 | Smithkline Beecham Corp | Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica |
| WO2009067397A2 (en) * | 2007-11-19 | 2009-05-28 | Ore Pharmaceuticals Inc. | Treatment for solid tumors |
| BR112014023517B1 (pt) * | 2012-03-22 | 2020-12-01 | The Regents Of The University Of Michigan | Usos de cloridrato de n-(2,6-bis(1-metiletil)fenil)-n-((1-(4-(dimetilamino)fenil)ciclopentil) metil)ureia para tratar distúrbios das células do córtex adrenal anormais |
-
2013
- 2013-03-13 BR BR112014023517-1A patent/BR112014023517B1/pt active IP Right Grant
- 2013-03-13 EP EP13712998.7A patent/EP2838523A1/en not_active Withdrawn
- 2013-03-13 AU AU2013235535A patent/AU2013235535B2/en active Active
- 2013-03-13 CN CN201610595176.5A patent/CN106236741A/zh active Pending
- 2013-03-13 IN IN8604DEN2014 patent/IN2014DN08604A/en unknown
- 2013-03-13 CA CA2867668A patent/CA2867668A1/en not_active Abandoned
- 2013-03-13 WO PCT/US2013/031068 patent/WO2013142214A1/en not_active Ceased
- 2013-03-13 JP JP2015501763A patent/JP6234987B2/ja active Active
- 2013-03-13 US US13/802,047 patent/US9107883B2/en active Active
- 2013-03-13 NZ NZ630828A patent/NZ630828A/en unknown
- 2013-03-13 MX MX2014011188A patent/MX355129B/es active IP Right Grant
- 2013-03-13 CN CN201380015269.0A patent/CN104302283B/zh active Active
- 2013-03-13 HK HK15107166.6A patent/HK1206607A1/xx unknown
-
2015
- 2015-07-13 US US14/798,237 patent/US9446010B2/en active Active
-
2016
- 2016-06-01 US US15/170,682 patent/US9877937B2/en active Active
-
2017
- 2017-06-26 JP JP2017124186A patent/JP6317016B2/ja active Active
- 2017-11-17 AU AU2017261632A patent/AU2017261632A1/en not_active Abandoned
- 2017-12-12 US US15/839,647 patent/US20180256524A1/en not_active Abandoned
-
2021
- 2021-06-30 US US17/364,464 patent/US20220160662A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014011188A (es) | 2015-03-06 |
| EP2838523A1 (en) | 2015-02-25 |
| AU2013235535A1 (en) | 2014-10-09 |
| JP2017160275A (ja) | 2017-09-14 |
| JP6317016B2 (ja) | 2018-04-25 |
| US20180256524A1 (en) | 2018-09-13 |
| MX355129B (es) | 2018-04-06 |
| CN104302283B (zh) | 2016-08-24 |
| AU2017261632A1 (en) | 2017-12-07 |
| CA2867668A1 (en) | 2013-09-26 |
| CN106236741A (zh) | 2016-12-21 |
| US20160367507A1 (en) | 2016-12-22 |
| AU2013235535B2 (en) | 2017-09-21 |
| US20220160662A1 (en) | 2022-05-26 |
| US20130267550A1 (en) | 2013-10-10 |
| US9107883B2 (en) | 2015-08-18 |
| BR112014023517B1 (pt) | 2020-12-01 |
| JP2015510933A (ja) | 2015-04-13 |
| JP6234987B2 (ja) | 2017-11-22 |
| US20160008302A1 (en) | 2016-01-14 |
| CN104302283A (zh) | 2015-01-21 |
| HK1206607A1 (en) | 2016-01-15 |
| IN2014DN08604A (enExample) | 2015-05-22 |
| WO2013142214A1 (en) | 2013-09-26 |
| US9877937B2 (en) | 2018-01-30 |
| US9446010B2 (en) | 2016-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630828A (en) | Compounds and methods for treating aberrant adrenocartical cell disorders | |
| BR112015019794A8 (pt) | Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto | |
| MX381987B (es) | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2 | |
| JOP20140104B1 (ar) | مركبات ثنائى اريل اميد كمثبطات كيناز | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| PH12014500468A1 (en) | Heterocyclic compounds and uses thereof | |
| BR112014005268A2 (pt) | compostos de amido como moduladores de ror t e usos dos mesmos | |
| HK1207069A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| BR112014015568A8 (pt) | compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MY199091A (en) | Therapeutic compounds | |
| WO2014179154A3 (en) | Novel compounds that are erk inhibitors | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| EA201791933A1 (ru) | Ингибирование активности olig2 | |
| HK1253373A1 (zh) | 使用替米沙坦预防和治疗移植物抗宿主病及其他同种免疫性和自体免疫性疾病 | |
| WO2014081714A3 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| NZ630033A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2018 BY AJ PARK Effective date: 20170523 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2019 BY COMPUTER PACKAGES INC Effective date: 20180220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2020 BY COMPUTER PACKAGES INC Effective date: 20190219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2022 BY BIRGIT KNAACK Effective date: 20210628 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2023 BY PAVIS PAYMENT GMBH Effective date: 20220303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2024 BY PAVIS PAYMENTS GMBH Effective date: 20230302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2025 BY BIRGIT KNAACK Effective date: 20240308 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2026 BY BIRGIT KNAACK Effective date: 20250303 |